Thu.Jan 02, 2025

article thumbnail

5 Mindsets That Create Success: A Stylist's Guide to Thinking Bigger in 2025

Salon Today

Success starts in the mind before it shows up in your bank account. Dawna Jarvis shares five mindset that can help stylists think bigger in 2025, along with action steps that make those goals reality.

97
article thumbnail

What’s Trending in the Esthetician Industry in 2025

Les Nouvelles Esthetics & Spa

Discover the top skincare trends of 2025, from Sculptural Face Lifting to AI-powered skin analysis, and learn how estheticians can stay ahead with personalized treatments, wellness integration, and sustainable practices. The post Whats Trending in the Esthetician Industry in 2025 appeared first on Les Nouvelles Esthtiques & Spa.

article thumbnail

Make Your 2025 Resolutions Stick

Salon Today

New Year's Resolutions are easy to make, but much harder to accomplish. Our Wellness Blogger Mary Wilson walks you through a simple strategy that helps you improve your chances of sticking to your resolution, then shares her personal goal as an example.

59
article thumbnail

The Dermatology Industry Landscape: Unpacking Economic and Mergers & Acquisitions Movements

Dermatology Times

The dermatology market remains an exciting space with strong demand for its valuable services, bolstered by positive US economic trends and robust consumer spending.

article thumbnail

Thompson Spa Adds Clinical Menu

Skin Inc

The new ThompsonRx menu of six facials using Skinceuticals products can be enjoyed my any skin type and are customized to each client to address acne, dull skin or aging.

Clinic 40
article thumbnail

Dermatology Conferences and Meetings Calendar: 2025

Dermatology Times

Dermatology Times asked our readers to share what conferences they are looking forward to in 2025.

More Trending

article thumbnail

Dermatology Conferences and Meetings Calendar: January 2025

Dermatology Times

Dermatology Times has compiled a list of dermatological meetings taking place during the month of January.

article thumbnail

RXI-231 May Help Fade Hyperpigmentation

The Dermatology Digest

RXI-231 may represent a promising approach to the treatment of hyperpigmentation, according to research in Clinical, Cosmetic and Investigational Dermatology. Phio Pharmaceuticals Corps RXI-231 is an INTASYL compound designed to target and reduce tyrosinase (TYR) gene expression. INTASYL siRNA gene silencing technology is designed to make the body’s immune cells more effective in killing cancer cells.

article thumbnail

Understanding Ruxolitinib’s Mechanism of Action in Atopic Dermatitis

Dermatology Times

The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.

article thumbnail

Discussing Nonsteroidal Topical Creams for Atopic Dermatitis With Patients

Dermatology Times

The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.

article thumbnail

Utilizing Safety Data When Prescribing Ruxolitinib Cream for Atopic Dermatitis

Dermatology Times

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36
article thumbnail

Managing Moderate Prurigo Nodularis in a 52-Year-Old Female With Atopic Dermatitis

Dermatology Times

A panelist discusses how diagnostic differentiation of prurigo nodularis requires careful examination of the characteristic firm, hyperkeratotic nodules and consideration of the patient's history of chronic pruritus and scratching behavior, while noting that comorbid atopic dermatitis may influence treatment selection toward dual-targeting therapies.

article thumbnail

Dual Approach to AD: Complementary Benefits of Dupilumab and JAK Inhibitors

Dermatology Times

Researchers found significant clinical benefits and tolerability with dual therapy for patients unresponsive to dupilumab alone.

Therapy 31